The CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

Find insight on Zydus Lifesciences, Biotech and more in the latest Market Talks covering the Health Care sector.

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Rare Guillain-Barré Syndrome cases were found after ChAdOx1 vaccine in India; vigilance is urged despite vaccine’s overall safety.

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.